S
Sapir Dreyer-Alster
Researcher at Sheba Medical Center
Publications - 6
Citations - 512
Sapir Dreyer-Alster is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Vaccination & Multiple sclerosis. The author has an hindex of 2, co-authored 6 publications receiving 146 citations.
Papers
More filters
Journal ArticleDOI
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Anat Achiron,Mathilda Mandel,Sapir Dreyer-Alster,Gil Harari,David Magalashvili,Polina Sonis,Mark Dolev,Shay Menascu,Shlomo Flechter,Rina Falb,Michael Gurevich +10 more
TL;DR: The National Multiple Sclerosis Society and other expert organizations recommended that all patients with MS should be vaccinated against COVID-19 as discussed by the authors, however, they did not recommend that all MS patients with mild relapses be vaccinated.
Journal ArticleDOI
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Anat Achiron,Mark Dolev,Shay Menascu,Daniela Noa Zohar,Sapir Dreyer-Alster,Shmuel Miron,Emanuel Shirbint,David Magalashvili,Shlomo Flechter,Uri Givon,Diana Guber,Yael Stern,Michael Polliack,Rina Falb,Michael Gurevich +14 more
TL;DR: In this article, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed, since vaccination against coronavirus disease 2019 (COVID-19) became available.
Journal ArticleDOI
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
Anat Achiron,Mathilda Mandel,Sapir Dreyer-Alster,Gil Harari,Mark Dolev,Shay Menascu,David Magalashvili,Shlomo Flechter,Uri Givon,Diana Guber,Polina Sonis,Rina Zilkha-Falb,Michael Gurevich +12 more
TL;DR: In this article, the authors determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects.
Journal ArticleDOI
Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
Journal ArticleDOI
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Anat Achiron,Mathilda Mandel,Sapir Dreyer-Alster,Gil Harari,David Magalashvili,Polina Sonis,Mark Dolev,Shay Menascu,Shlomo Flechter,Rina Falb,Michael Gurevich +10 more